|
Research Management and Support
|
RMS2009 [E]
|
$350,982,837
|
N/A
|
National Cancer Institute
|
|
Phospholipid and Sphingolipid Signaling in Drosophila
|
ZIA BC 010331
|
$366,973
|
Acharya, Jairaj
|
CCR (NCI)
|
|
Sphingolipid Signaling in Mammals
|
ZIA BC 011187
|
$366,973
|
Acharya, Jairaj
|
CCR (NCI)
|
|
2009 World Molecular Imaging Congress
|
1R13CA142041-01
|
$5,000
|
ACKERMAN, JOSEPH
|
SOCIETY FOR MOLECULAR IMAGING
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$728,095
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Protein Folding Mechanism
|
ZIA BC 010276
|
$239,235
|
Bai, Yawen
|
CCR (NCI)
|
|
Clinical Pharmacology of Anticancer Drugs
|
ZIA BC 011080
|
$923,641
|
Balis, Frank
|
CCR (NCI)
|
|
Anticancer Drug Development for Childhood Cancers
|
ZIA SC 006880
|
$831,277
|
Balis, Frank
|
CCR (NCI)
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Matrix Metalloproteinases Gordon Conference
|
5R13CA115182-03
|
$5,000
|
Blobel, Carl
|
GORDON RESEARCH CONFERENCES
|
|
Studies of Histone Functions in Chromatin; H2AX and DNA DSBs
|
ZIA BC 006140
|
$791,053
|
Bonner, William
|
CCR (NCI)
|
|
Molecular Profiling of Patients Undergoing Radiotherapy
|
ZIA SC 010372
|
$703,565
|
Camphausen, Kevin
|
CCR (NCI)
|
|
The Synergy Between Radiotherapy and Molecularly Targeted Agents
|
ZIA SC 010373
|
$1,055,348
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Radiation Oncology Branch - Radiation Clinic
|
ZID BC 010990
|
$4,519,561
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors
|
5R01CA122804-02
|
$300,875
|
CARROLL, STEVEN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Regulation of Leukocyte Integrins in Inflammatory Cell Recruitment
|
ZIA BC 010790
|
$347,408
|
Chavakis, Triantafyllos
|
CCR (NCI)
|
|
Regulating Neuroendocrine Phenotype in Cancer
|
5R01CA109053-04
|
$202,687
|
CHEN, HERBERT
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Dynamic Regulation of Ras via the NF1 tumor Suppressor
|
5R01CA111754-05
|
$286,105
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis
|
5R01CA129814-03
|
$321,811
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Neurofibromatosis type 1 Gene Regulates Myelopoiesis
|
5R01CA074177-12
|
$325,689
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Trans-NIH Angiogenesis Core Facility
|
ZIC BC 010964
|
$882,625
|
Cuttitta, Frank
|
CCR (NCI)
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$437,219
|
Daar, Ira
|
CCR (NCI)
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$437,219
|
Daar, Ira
|
CCR (NCI)
|
|
Cancer Center Clinical Trials Reporting Program (CTRP) Early Adopters
|
3P30CA013696-36S1
|
$99,928
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-36
|
$3,999,822
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Complex Human Diseases - From Gene to Function to Therapy
|
ZIA BC 005725
|
$517,266
|
Dean, Michael
|
CCR (NCI)
|
|
Molecular Modeling of Ion Channel and Other Membrane Proteins
|
ZIC BC 011071
|
$47,375
|
Durell, Stewart
|
CCR (NCI)
|
|
Clinical Pharmacogenetics
|
ZIA BC 010627
|
$438,328
|
Figg, William
|
CCR (NCI)
|
|
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
|
ZIA BC 010839
|
$539,975
|
Fine, Howard
|
CCR (NCI)
|
|
Elucidation and Exploitation of GSK3 as a Novel Glioma Therapeutic Target
|
ZIA BC 010840
|
$472,478
|
Fine, Howard
|
CCR (NCI)
|
|
Canine Glioma and Embryonic Neural Stem Cell Project
|
ZIA BC 011099
|
$472,478
|
Fine, Howard
|
CCR (NCI)
|
|
SCF as a Novel CNS and Glioma-Derived Angiogenic Factor and SC Chemotaxic Factor
|
ZIA BC 011100
|
$539,975
|
Fine, Howard
|
CCR (NCI)
|
|
Identifying New Glioma-Associated Tumor Suppressors and Oncogenes
|
ZIA BC 011101
|
$539,975
|
Fine, Howard
|
CCR (NCI)
|
|
The Role of miRNAs in Glioma Stem Cell and Glioma Biology
|
ZIA BC 011102
|
$539,975
|
Fine, Howard
|
CCR (NCI)
|
|
The Glioma Molecular Diagnostic Initiative: Characterizing Brain Tumor Data
|
ZIA SC 010100
|
$877,459
|
Fine, Howard
|
CCR (NCI)
|
|
Brain Tumor Animal Therapeutics Core
|
ZIC BC 011086
|
$607,472
|
Fine, Howard
|
CCR (NCI)
|
|
Brain Tumor Clinical and Clinical Research Program
|
ZID BC 011098
|
$2,159,900
|
Fine, Howard
|
CCR (NCI)
|
|
Identification and characterization of new mutants affecting Notch trafficking
|
ZIA BC 010913
|
$149,462
|
Fortini, Mark
|
CCR (NCI)
|
|
Connecting PTEN and NF2 cancer predisposition syndromes
|
5R01CA107201-05
|
$254,494
|
GEORGESCU, MARIA-MAGDALENA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Serum Antibody Profiling with a Carbohydrate Microarray
|
ZIA BC 011055
|
$258,885
|
Gildersleeve, Jeffrey
|
CCR (NCI)
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$956,040
|
Gottesman, Michael
|
CCR (NCI)
|
|
Modeling of the structure and functional mechanisms of voltage-gated channels
|
ZIA BC 010721
|
$192,861
|
Guy, H. Robert
|
CCR (NCI)
|
|
Modeling of amyloid peptides and proteins
|
ZIA BC 010722
|
$321,435
|
Guy, H. Robert
|
CCR (NCI)
|
|
Developing Improved Methods for Modeling and Simulating Protein Structures
|
ZIA BC 011060
|
$128,574
|
Guy, H. Robert
|
CCR (NCI)
|
|
Role of Selenium in Cancer and Health
|
ZIA BC 005317
|
$448,935
|
Hatfield, Dolph
|
CCR (NCI)
|
|
Role of Selenium-containing Proteins in Cancer and Development
|
ZIA BC 010889
|
$224,467
|
Hatfield, Dolph
|
CCR (NCI)
|
|
Cutaneous Lesions in Neurofibromatosis Type I and Other Pre-cancerous Syndromes
|
ZIA BC 010734
|
$43,418
|
Hornyak, Thomas
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|